Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT01329731 |
Date of registration:
|
01/04/2011 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients
|
Scientific title:
|
White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months |
Date of first enrolment:
|
March 2011 |
Target sample size:
|
48 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT01329731 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
Phase:
|
Phase 4
|
|
Countries of recruitment
|
Germany
| | | | | | | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Written informed consent
- Healthy volunteers (=11 years) scheduled for bracket removal
- = 1 WSL with a modified score 1 or 2 (Gorelick et al. 1982) on UFT at debonding
Exclusion Criteria:
- Known hypersensitivity or allergy to study products and standard toothpaste
ingredients and/or dental material used in the present study
- Known hypersensitivity or allergy to placebo gel ingredients
- Alterations in the teeth's enamel, e.g. hypoplasia, fluorosis
- Any illness/condition potentially affecting the study outcome at investigator's
discretion
- Known pregnancy or breast feeding during the course of the study
Age minimum:
11 Years
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Tooth; Lesion, White Spot Lesions
|
Intervention(s)
|
Drug: negative control (placebo)
|
Drug: elmex® gelée
|
Primary Outcome(s)
|
WSL-size change
[Time Frame: 12 weeks]
|
Secondary Outcome(s)
|
Caries activity
[Time Frame: Baseline up to 24 weeks]
|
WSL index on all upper front teeth
[Time Frame: Baseline up to 24 weeks]
|
DMFT index: Dental health of all teeth
[Time Frame: Baseline, 24 weeks]
|
WSL-size change
[Time Frame: Baseline up to 24 weeks]
|
Gingival bleeding index on all upper front teeth
[Time Frame: Baseline up to 24 weeks]
|
Plaque index (Silness and Löe 1964)on all upper front teeth
[Time Frame: Baseline up to 24 weeks]
|
WSL-brightness change
[Time Frame: Baseline up to 24 weeks]
|
Secondary ID(s)
|
2010-020538-24
|
GASAS-1002X
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|